The goal is to determine if providing a nutritional supplement, phosphatidylcholine, to
pregnant women improves early brain development with improved brain-related development
during the first four years of life. Participating pregnant women will receive either
phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The
primary outcome is the child's behavior at four years of age as reported by the primary
caregiver. Secondary outcomes include motor development, socio-emotional development,
language development, and cognitive development. Potential contributors beyond the
supplement, including maternal stress and placental function will also be assessed.